Academic Research Lab Uses ONCOPREX Delivery System to Restore FAS Expression in Mouse Metastatic Colon-Cancer Cells
Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is a leader in gene therapy with a systemic gene therapy in development for non-small cell lung cancer (NSCLC).
Multiple clinical trial sites to be opened under oncology research network collaboration
original article: FDA Grants Fast Track Designation to Quaratusugene Ozeplasmid Immunogene Therapy Plus Pembrolizumab for NSCLC (cancernetwork.com)
original article: FDA Grants Fast Track Designation for Reqorsa in Combination with Keytruda for NSCLC (pharmacytimes.com)
HC Wainwright BIOCONNECT 2022 Virtual Conference - January 10-13 Biotech Showcase 2022 - January 10-13 Precision: Lung Cancer World R&D Virtual Summit - January 25-26 CEO Roadshow - January 26
original article: FDA grants Fast Track status to Genprex’s drug for NSCLC treatment (pharmaceutical-technology.com)
Pipeline Expansion Enables Company to Target Entire Lung Cancer Market with REQORSA™
original article: FDA Grants Fast Track Status to Novel Gene Therapy Plus Pembrolizumab for Late-Stage NSCLC (onclive.com)
Second FDA Fast Track Designation Further Validates the Potential of REQORSA
Designed and Secured by Barsec